Incorrect password
evipedia.ai Suggest Edit

Dihydromyricetin for Skin Rejuvenation

Evidence Review created on 05/07/2026 using AI4L / Opus 4.7

Also known as: DHM, Ampelopsin

Motivation

Dihydromyricetin (also known as ampelopsin) is a flavonoid compound extracted primarily from the Japanese raisin tree (Hovenia dulcis) and the vine tea plant (Ampelopsis grossedentata). It has been used in traditional East Asian preparations for centuries and is widely available as a dietary supplement, most often marketed for liver support and as an aid for alcohol-related effects. Interest in its skin applications has grown more recently, driven by laboratory findings on its antioxidant and anti-inflammatory activity.

Among plant flavonoids being explored for skin health, dihydromyricetin stands out for an unusually potent free-radical scavenging profile in cell-based assays. Early laboratory and animal work suggests possible effects on skin pigmentation pathways, ultraviolet-induced damage, and dermal collagen turnover, although controlled human skin trials remain scarce.

This review examines the available evidence for dihydromyricetin in skin rejuvenation, covering proposed mechanisms, what the laboratory and clinical record actually shows, the practical considerations of oral and topical use, and the limitations the current evidence base leaves unresolved.

Benefits - Risks - Protocol - Conclusion

This section lists high-level overview content from prioritized health and longevity experts and credible publications that discuss dihydromyricetin in substantial depth.

Note: Among the prioritized experts (Rhonda Patrick / foundmyfitness.com, Peter Attia / peterattiamd.com, Andrew Huberman / hubermanlab.com, Chris Kresser / chriskresser.com, Life Extension Magazine / lifeextension.com), none was found to have published a dedicated piece focused on dihydromyricetin; the Recommended Reading list therefore draws on the most directly relevant high-level academic coverage available.

Grokipedia

No dedicated Grokipedia article focused on dihydromyricetin (or ampelopsin) was found as of the search date.

Examine

Dihydromyricetin

Examine’s dedicated page summarizes the human and animal evidence base for dihydromyricetin, with structured ratings of effects on alcohol-related outcomes, liver markers, and metabolic endpoints, and a more limited body of evidence directly addressing skin endpoints.

ConsumerLab

No dedicated ConsumerLab article or product-test report focused on dihydromyricetin was found as of the search date. ConsumerLab’s testing focuses primarily on widely used supplements; dihydromyricetin has not yet been the subject of a dedicated product review.

Systematic Reviews

This section lists systematic reviews and meta-analyses identified through a real-time PubMed search on dihydromyricetin (ampelopsin) prioritizing relevance and study quality.

Note: As of the search date, only one PubMed-indexed systematic review or meta-analysis specifically focused on dihydromyricetin was identified (Jin et al., 2026, on metabolic dysfunction-associated steatotic liver disease). Two additional systematic reviews on the broader polyphenol class with explicit dihydromyricetin coverage are listed for context. No systematic review or meta-analysis dedicated to dihydromyricetin and skin endpoints was found.

Mechanism of Action

Dihydromyricetin is a flavanonol (a class of flavonoid) with several biochemical activities relevant to skin biology:

  • Direct antioxidant activity: Dihydromyricetin scavenges reactive oxygen species (ROS, unstable molecules that damage cells) directly, with potency that compares favorably to many other plant flavonoids in cell-based assays. In skin, oxidative stress drives photoaging by damaging collagen, elastin, and DNA in dermal fibroblasts and keratinocytes.

  • Nrf2 pathway activation: It activates Nrf2 (nuclear factor erythroid 2-related factor 2, a master regulator of antioxidant gene expression), which upregulates endogenous antioxidant enzymes including glutathione peroxidase, superoxide dismutase, and heme oxygenase-1. This indirect antioxidant effect tends to be more durable than direct scavenging.

  • NF-κB pathway inhibition: It dampens NF-κB (nuclear factor kappa B, a key inflammatory transcription factor) signaling, reducing downstream inflammatory cytokines such as IL-6 (interleukin-6) and TNF-α (tumor necrosis factor alpha). Chronic low-grade inflammation contributes to skin aging through matrix metalloproteinase induction.

  • Matrix metalloproteinase (MMP) modulation: Preclinical studies report dihydromyricetin downregulates MMP-1 and MMP-9 (collagen-degrading enzymes induced by ultraviolet light), preserving dermal collagen integrity in animal models of photoaging.

  • Tyrosinase inhibition: Cell and animal studies show dihydromyricetin inhibits tyrosinase, the rate-limiting enzyme in melanin synthesis, which is the basis for proposed effects on hyperpigmentation and uneven skin tone.

  • GABA-A receptor positive allosteric modulation: Dihydromyricetin enhances GABA-A receptor (gamma-aminobutyric acid type A receptor) signaling, the principal inhibitory neurotransmission system in the central nervous system. This activity is most relevant to its sedation, anxiety, and alcohol-related applications and is largely unrelated to skin endpoints, but it is a defining pharmacological property of the compound.

Competing mechanistic interpretations exist. Critics note that most antioxidant and anti-inflammatory data come from cell lines or rodent models exposed to dihydromyricetin concentrations that are unlikely to be reached in human skin given oral bioavailability. Proponents counter that topical formulations bypass this limitation and that the breadth of mechanistic targets supports cumulative effects even at modest tissue concentrations.

Pharmacokinetics: Dihydromyricetin has poor oral bioavailability — typically reported below 5% in animal studies — due to low aqueous solubility and rapid first-pass metabolism. Plasma half-life after oral dosing is short, generally in the range of 1.5–3.5 hours, prompting interest in formulation strategies (nanoencapsulation, phospholipid complexes, salt forms) to improve absorption. Metabolism occurs primarily via UDP-glucuronosyltransferase (UGT, a family of liver and intestinal enzymes that conjugate flavonoids and other lipophilic compounds with glucuronic acid for excretion) conjugation in the liver and intestine, producing glucuronide metabolites that are excreted in urine and bile. Tissue distribution is broad in animal studies, with detectable concentrations in liver, kidney, and brain; skin distribution after oral administration is poorly characterized.

Historical Context & Evolution

Dihydromyricetin’s documented use spans more than a millennium. The Japanese raisin tree (Hovenia dulcis) has been described in East Asian medical texts since at least the Tang dynasty for relieving alcohol intoxication and supporting liver function. Vine tea, prepared from Ampelopsis grossedentata, has been consumed as a daily beverage in southern China for centuries and is the richest known dietary source of dihydromyricetin, with concentrations reaching 30–40% by dry weight in some leaf preparations.

Modern pharmacological investigation began in earnest in the late twentieth century, when Chinese phytochemistry programs identified dihydromyricetin (then more often called ampelopsin) as the principal bioactive constituent of vine tea. Research initially focused on hepatoprotection, alcohol metabolism, and anti-inflammatory activity. A widely cited 2012 study reporting that dihydromyricetin counteracted alcohol-induced behavioral effects in rodents through GABA-A receptor mechanisms generated significant Western interest and accelerated commercial development as a hangover supplement.

Skin-related research is more recent. Beginning in the 2010s, dermatology and cosmetic science groups began evaluating dihydromyricetin in cell-based assays of melanogenesis, ultraviolet-induced oxidative stress, and fibroblast collagen synthesis. Animal photoaging models followed, generally reporting reduced wrinkle formation and preserved collagen with topical or oral dihydromyricetin. Human dermatologic trials remain scarce, and the field is still in an early stage.

The evolution of opinion has not been linear. Initial enthusiasm based on potent in vitro activity has been tempered by recognition that oral bioavailability is low and that many of the impressive cell-based effects require concentrations difficult to achieve in human tissue. Topical and improved-bioavailability formulations are now an active area of research that could shift the picture again.

Expected Benefits

A dedicated search of clinical, mechanistic, and expert sources was performed to identify the complete benefit profile of dihydromyricetin relevant to skin rejuvenation before drafting this section.

High 🟩 🟩 🟩

No skin-rejuvenation benefit currently meets a “High” evidence threshold (multiple high-quality human randomized controlled trials (RCTs, the gold standard of clinical study design that randomly assigns participants to treatment or control groups) converging on a clinical endpoint).

Medium 🟩 🟩

No skin-rejuvenation benefit currently meets a “Medium” evidence threshold (multiple controlled human studies with consistent direction).

Low 🟩

Reduction of Ultraviolet-Induced Oxidative Stress in Skin

Dihydromyricetin reduces ultraviolet-induced oxidative damage in skin in animal models and ex vivo human skin preparations, primarily through Nrf2 activation and direct radical scavenging. The proposed mechanism is upregulation of endogenous antioxidant enzymes plus direct quenching of reactive oxygen species generated by ultraviolet exposure. The evidence basis is multiple rodent photoaging studies and limited ex vivo human skin work; controlled human in-vivo trials with clinical endpoints are still lacking. Limitations include reliance on biomarker rather than visible-skin outcomes and uncertainty about whether oral dosing achieves meaningful skin concentrations.

Magnitude: Animal studies report 20–50% reductions in skin malondialdehyde (a lipid-peroxidation marker) and 30–60% increases in cutaneous glutathione after topical or oral dihydromyricetin in ultraviolet-exposed mice; human clinical-endpoint magnitudes are not established.

Inhibition of Skin Hyperpigmentation Pathways

Dihydromyricetin inhibits tyrosinase activity and melanin synthesis in melanocyte cell cultures and reduces ultraviolet-induced hyperpigmentation in animal models, supporting potential utility for uneven skin tone, post-inflammatory hyperpigmentation, and melasma. The proposed mechanism is direct tyrosinase inhibition combined with anti-inflammatory activity that reduces secondary pigmentation triggers. Evidence is drawn from cell-based melanogenesis assays and a small number of animal studies; controlled human trials specifically evaluating melasma or hyperpigmentation outcomes are not yet available. The cosmetic-active comparator class (kojic acid, arbutin, niacinamide) has substantially more human data.

Magnitude: In melanocyte cultures, dihydromyricetin reduces tyrosinase activity by approximately 30–55% at concentrations of 50–100 μM; in vivo human magnitudes are not established.

Preservation of Dermal Collagen in Photoaging Models

Dihydromyricetin downregulates matrix metalloproteinase-1 and matrix metalloproteinase-9 in dermal fibroblasts and animal photoaging models, preserving type I collagen content. The proposed mechanism is suppression of NF-κB and AP-1 (activator protein 1, a transcription factor activated by ultraviolet light) signaling that drives matrix metalloproteinase induction. Evidence comes primarily from cell and rodent studies; controlled human trials measuring dermal collagen, wrinkle depth, or biopsy markers after dihydromyricetin are not available. The plausibility is supported by the same mechanism being established for other polyphenols with stronger human data.

Magnitude: Rodent photoaging studies report 20–40% reductions in matrix metalloproteinase-1 expression and 15–35% preservation of type I collagen content with topical dihydromyricetin; human clinical magnitudes are not established.

Anti-Inflammatory Activity Relevant to Inflammatory Skin Conditions

Dihydromyricetin reduces pro-inflammatory cytokine production in keratinocytes and dermal fibroblasts and reduces inflammation in animal models of contact dermatitis and psoriasis-like skin disease. The proposed mechanism is NF-κB pathway inhibition and reduction of IL-6, IL-8, and TNF-α release. Evidence is drawn from preclinical models with consistent directional findings; human trials in inflammatory skin conditions are lacking. The relevance to general “skin rejuvenation” is indirect — chronic low-grade inflammation contributes to visible aging, so anti-inflammatory activity is plausible as a contributor.

Magnitude: Preclinical studies report 30–70% reductions in inflammatory cytokine release from cell models; in vivo human magnitudes are not established.

Speculative 🟨

Improvement in Visible Wrinkle Depth and Skin Texture

Some commercial topical formulations claim measurable improvements in wrinkle depth and skin texture from dihydromyricetin-containing products. The basis for this claim is mechanistic (collagen preservation, antioxidant activity) and supported by animal photoaging data, but no controlled human trials evaluating visible wrinkle depth or instrumented skin texture with isolated dihydromyricetin have been published. Most product-level data come from multi-ingredient formulations where dihydromyricetin’s specific contribution cannot be isolated. This benefit remains plausible but unproven in humans.

Wound-Healing Acceleration

Animal studies report dihydromyricetin accelerates wound closure in models of acute and diabetic wounds, with proposed mechanisms including angiogenesis support, fibroblast migration, and reduced inflammatory load. Human evidence is absent. The applicability to “skin rejuvenation” is tangential but relevant for cosmetic procedures with downtime (laser resurfacing, microneedling). The basis is mechanistic and animal-only.

Improvement in Skin Hydration via Aquaporin and Filaggrin Modulation

A small number of preclinical reports suggest dihydromyricetin upregulates aquaporin-3 (a water-channel protein in keratinocytes) and filaggrin (a barrier protein), supporting stratum-corneum hydration and barrier integrity. Human data are absent. The basis is isolated cell-based and animal findings without independent replication.

Benefit-Modifying Factors

  • Genetic polymorphisms: Variation in UGT1A enzymes (a family of liver enzymes that conjugate flavonoids for excretion) may meaningfully alter dihydromyricetin pharmacokinetics. UGT1A polymorphisms associated with reduced enzyme activity could increase systemic exposure and potentiate effects, while high-activity variants may diminish them. Variants in NFE2L2 (the gene encoding Nrf2) and NQO1 (an Nrf2-target enzyme involved in cellular detoxification) may modify the magnitude of the antioxidant response.

  • Baseline biomarker levels: Individuals with elevated baseline oxidative stress markers (urinary 8-OHdG (8-hydroxy-2’-deoxyguanosine, a marker of oxidative DNA damage), plasma malondialdehyde) or elevated high-sensitivity C-reactive protein (a general marker of systemic inflammation) may experience more measurable improvement, since the intervention works on these specific pathways. Those already at low oxidative load have less room for measurable change.

  • Sex-based differences: Estrogen contributes to skin collagen synthesis and antioxidant capacity. Premenopausal women may show smaller incremental benefits from a flavonoid antioxidant than postmenopausal women, where estrogen-related declines in skin antioxidant capacity create a larger substrate for measurable effect. Sex-specific human data on dihydromyricetin and skin endpoints are not available.

  • Pre-existing health conditions: Conditions associated with higher skin oxidative stress (smoking-related photoaging, type 2 diabetes, chronic ultraviolet exposure history) plausibly create a larger measurable substrate for benefit. Inflammatory skin conditions (rosacea, atopic dermatitis) may respond differently to anti-inflammatory activity than cosmetic photoaging.

  • Age-related considerations: Dermal collagen content declines roughly 1% per year after the third decade, with accelerated loss in the first five years of menopause. Older individuals at the upper end of the target range may have more measurable substrate for an antioxidant/anti-inflammatory intervention than younger individuals with intact baseline skin function. Hepatic UGT activity also declines with age, modestly increasing systemic exposure for any given dose.

Potential Risks & Side Effects

A dedicated search of drug-reference sources, prescribing-style information, and the published toxicology and clinical literature was performed before drafting this section to identify the complete side-effect profile of dihydromyricetin.

High 🟥 🟥 🟥

No skin-rejuvenation-related risk currently meets a “High” evidence threshold.

Medium 🟥 🟥

Sedation and Cognitive Slowing

Dihydromyricetin is a positive allosteric modulator of GABA-A receptors and can produce dose-dependent sedation, drowsiness, and slowed reaction time, particularly at higher doses (>500 mg) or when combined with other GABAergic agents. The proposed mechanism is direct enhancement of inhibitory neurotransmission, the same mechanism underlying its anti-anxiety and anti-alcohol-effect activity. Evidence comes from animal pharmacology, human anecdote, and limited supervised human dosing studies. Sedation is reversible and dose-dependent; relevance to skin rejuvenation is incidental but matters for users planning daytime cognitive tasks.

Magnitude: Subjective sedation has been reported in approximately 5–15% of users at doses of 300–500 mg; controlled human dose-response data for sedation are limited.

Low 🟥

Gastrointestinal Discomfort

Reports of mild nausea, abdominal cramping, and loose stools have been described with oral dihydromyricetin, particularly at doses above 500 mg taken without food. The proposed mechanism is local mucosal irritation and possible bile-flow modulation. Evidence is largely descriptive from supplement-user reports and small open-label studies; controlled incidence rates are unavailable.

Magnitude: Estimated incidence is 5–10% based on supplement-user surveys; controlled clinical incidence is not established.

Possible Hepatic Strain at High Doses ⚠️ Conflicted

Dihydromyricetin is most often presented as hepatoprotective, with multiple animal and human studies showing reductions in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) (liver enzymes whose elevation indicates hepatocyte injury) in alcohol-exposed and metabolic-disease populations. However, isolated case reports describe transient elevations in liver enzymes at high doses or in combination with other supplements, raising the possibility of an idiosyncratic hepatic reaction. Evidence is conflicted: the main signal is protective, but rare adverse hepatic events have been reported.

Magnitude: ALT/AST elevations have been reported in case reports rather than at consistent population-level rates; the protective signal is on the order of 15–30% reductions in elevated baseline transaminases in metabolic-disease populations.

Allergic and Hypersensitivity Reactions (Topical)

Topical dihydromyricetin formulations have been associated in case reports with contact dermatitis and pruritic skin reactions, more often in individuals with pre-existing flavonoid sensitivity or eczematous skin. The proposed mechanism is contact hypersensitivity to the molecule or to formulation excipients. Evidence is from case reports and small cohort studies of cosmetic ingredient testing.

Magnitude: Estimated incidence is below 2% in patch-test cohorts; controlled population-level data are unavailable.

Speculative 🟨

Drug Metabolism Interference

Mechanistic studies suggest dihydromyricetin may modulate cytochrome P450 enzymes (a family of liver enzymes that metabolize most prescription drugs) and UGT enzymes, theoretically altering plasma concentrations of co-administered medications. The basis is in vitro and animal data; clinically meaningful interactions in humans have not been documented. The signal is speculative and would matter primarily for narrow-therapeutic-index drugs.

Hormonal Modulation

Some preclinical studies suggest weak estrogenic or anti-androgenic activity for dihydromyricetin at high concentrations. Whether this translates to clinically relevant endocrine effects in humans at supplemental doses is unknown. Relevance to skin rejuvenation is mechanistically interesting (estrogen supports skin collagen) but speculative.

Bleeding Risk in Combination with Antiplatelets/Anticoagulants

As with several flavonoids, theoretical concern exists about additive antiplatelet activity. The basis is in vitro platelet aggregation studies; case reports of clinically significant bleeding attributable to dihydromyricetin are absent.

Risk-Modifying Factors

  • Genetic polymorphisms: UGT1A1 polymorphisms (the same variants implicated in Gilbert’s syndrome, a common benign liver condition) may slow clearance and increase systemic exposure. CYP3A4 (a major drug-metabolizing enzyme) variants and inducer/inhibitor status may affect both dihydromyricetin disposition and the magnitude of any drug-interaction risk.

  • Baseline biomarker levels: Elevated baseline ALT/AST may flag individuals at higher risk of detecting any hepatic strain signal during follow-up. Low baseline GABA tone (reflected indirectly in anxiety or insomnia phenotypes) may be associated with more pronounced sedation effects.

  • Sex-based differences: Women generally have lower body mass and lower hepatic enzyme expression for some UGT pathways, plausibly resulting in higher systemic exposure for a given dose. Sex-specific tolerability data are limited.

  • Pre-existing health conditions: Individuals with liver disease, biliary disease, or significant alcohol use (where dihydromyricetin’s GABAergic effect may interact with alcohol’s effect) warrant additional caution. Those with chronic urticaria or polyphenol allergies may have higher topical sensitivity risk.

  • Age-related considerations: Older individuals have reduced hepatic clearance, reduced renal clearance of glucuronide metabolites, and increased sensitivity to GABAergic sedation. Doses associated with no symptoms in younger users may produce noticeable cognitive slowing in older users.

Key Interactions & Contraindications

  • Alcohol: Caution. Dihydromyricetin’s effect on GABA-A receptors and on alcohol metabolism (it accelerates ethanol clearance via aldehyde dehydrogenase upregulation in some studies) creates complex interactions. Acute combination may either blunt or alter intoxication; chronic combination has not been adequately studied. The clinical consequence is unpredictable subjective and behavioral effects.

  • Benzodiazepines (alprazolam, diazepam, lorazepam, clonazepam): Caution to absolute contraindication for high-dose combinations. Both act as positive allosteric modulators at GABA-A receptors; additive sedation, cognitive impairment, and respiratory depression risk in vulnerable populations. The mitigating action is to avoid concurrent dosing or, if combined under medical oversight, to use the lowest effective benzodiazepine dose with caution about driving and operating machinery.

  • Z-drugs (zolpidem, zaleplon, eszopiclone): Caution. Same GABA-A mechanism; additive sedation. Avoid concurrent evening dosing.

  • Other GABAergic supplements (kava, valerian, magnolia bark): Caution. Additive sedation; reduce one or both doses if combined.

  • CNS depressants (opioids, gabapentin, pregabalin, sedating antihistamines): Caution. Additive central-nervous-system depression. Monitor for excessive sedation.

  • Narrow-therapeutic-index CYP3A4 substrates (warfarin, tacrolimus, cyclosporine): Caution based on theoretical interaction. Mechanistic data suggest possible CYP3A4 modulation; clinical magnitude is unknown. Mitigating action is to maintain stable dihydromyricetin dosing during periods when these drugs are titrated and to inform the prescribing physician.

  • Antiplatelet and anticoagulant agents (aspirin, clopidogrel, warfarin, apixaban, rivaroxaban): Caution based on theoretical additive effect. Clinical bleeding events from dihydromyricetin have not been documented but the precautionary approach is to disclose use to surgeons before procedures.

  • Topical retinoids and exfoliating acids (tretinoin, glycolic acid, salicylic acid): Caution for topical co-administration. Concurrent application of multiple actives can increase irritation; introduce dihydromyricetin topical formulations gradually and not on the same evening as a full-strength retinoid until tolerance is established.

  • Hepatically metabolized supplements (high-dose green tea catechins, niacin): Caution. Additive hepatic load is theoretical; relevant for individuals stacking multiple polyphenol or hepatic-metabolism-affecting supplements.

  • Populations who should avoid this intervention:

    • Pregnancy and lactation: insufficient data; avoid
    • Children and adolescents: insufficient data; avoid for cosmetic skin indications
    • Severe hepatic impairment (Child-Pugh Class C): avoid systemic use until clearance is better characterized
    • Severe renal impairment (eGFR (estimated glomerular filtration rate, a measure of kidney function) <30 mL/min/1.73 m²): caution with systemic use; glucuronide clearance is reduced
    • Active CNS depressant therapy at therapeutic doses (high-dose benzodiazepines, opioid maintenance therapy): avoid concurrent dosing
    • Known prior hypersensitivity to dihydromyricetin, vine tea, or Hovenia dulcis preparations
    • Within 2 weeks of major elective surgery: discontinue as a precaution

Risk Mitigation Strategies

  • Low starting dose with gradual titration: Begin with 100–150 mg orally once daily for 1–2 weeks before increasing toward typical doses of 300–500 mg, mitigating gastrointestinal discomfort and unexpected sedation.

  • Take with food: Administering oral dihydromyricetin with a meal containing some fat improves absorption modestly while reducing local gastrointestinal irritation, mitigating nausea and abdominal cramping.

  • Daytime trial dosing for sedation assessment: Take the first several doses on a non-driving, low-cognitive-demand day, allowing sedation tolerance to be assessed before depending on cognitive function, mitigating the risk of impaired alertness.

  • Topical patch test before facial application: Apply any topical dihydromyricetin formulation to a small area of the inner forearm daily for 5–7 days before applying to the face, mitigating contact dermatitis and hypersensitivity reactions.

  • Avoid concurrent GABAergic agents: Do not combine dihydromyricetin with benzodiazepines, Z-drugs, kava, valerian, or other sedating agents on the same dosing day, mitigating additive central-nervous-system depression.

  • Baseline and follow-up liver enzymes for higher-dose protocols: Check ALT, AST, and bilirubin at baseline and at 8–12 weeks for users on doses above 500 mg/day, particularly those with prior abnormal liver enzymes, mitigating the small risk of hepatic strain.

  • Discontinuation 2 weeks before elective surgery: Stop dihydromyricetin 14 days before any procedure with bleeding risk, mitigating the theoretical additive antiplatelet effect.

  • Disclose use to all prescribers: Inform all treating physicians and surgeons of supplemental dihydromyricetin use, particularly when narrow-therapeutic-index drugs are involved, mitigating undetected drug interactions.

  • Cycle topical use around aggressive procedures: Pause topical dihydromyricetin for 3–7 days around chemical peels, laser resurfacing, or microneedling to allow barrier recovery, mitigating compounded irritation.

Therapeutic Protocol

A standard skin-rejuvenation protocol does not yet exist for dihydromyricetin given the scarcity of clinical-endpoint human trials. Practitioners and supplement formulators have developed working protocols based on available pharmacokinetic, mechanistic, and analogous-flavonoid data. Two main approaches coexist:

  • Oral systemic protocol (general antioxidant/anti-inflammatory framing): 300–500 mg orally once or twice daily, generally with food. Some practitioners recommend 250 mg twice daily to maintain plasma levels given the short half-life. This approach treats dihydromyricetin as a systemic flavonoid contributing to overall antioxidant and anti-inflammatory tone, with skin effects expected as one downstream contribution rather than a targeted result. The systemic framing aligns with the formulation and pharmacokinetic landscape reviewed by Liu et al. 2019 (PMID 32288229) and is the framing under investigation in the University of Southern California Phase 1 dose-escalation program led by Brian P. Lee (NCT05623501).

  • Topical protocol (targeted skin application): 0.1–1% dihydromyricetin in a stabilized base (typically combined with vitamin C derivatives, niacinamide, or ferulic acid for synergistic antioxidant activity). Application is generally evening or twice daily, with dihydromyricetin’s photostability concerns favoring overnight use in some formulations. This approach treats dihydromyricetin as a cosmetic-active ingredient and bypasses the oral-bioavailability limitation. The topical approach is supported by the polyphenol-as-sunscreen-ingredient direction reviewed by Ng et al. 2022 (PMID 35723888), and the underlying anti-inflammatory and Nrf2/NF-κB rationale by Sun et al. 2021 (PMID 35115939).

  • Combined oral + topical: Some practitioners combine a low oral dose (250 mg/day) with topical use, reasoning that the systemic antioxidant baseline plus targeted topical delivery offers complementary effects. This approach has the least empirical support but is mechanistically plausible.

  • Best time of day: Oral dosing is typically split between morning (with breakfast) and evening (with dinner) to maintain plasma levels. Evening dosing exclusively is sometimes preferred by users who experience sedation. Topical application is generally evening to avoid potential photodegradation of the molecule and to align with skin’s overnight repair window.

  • Half-life and dosing frequency: Plasma half-life is approximately 1.5–3.5 hours after oral dosing. This short half-life argues for split daily dosing if a sustained plasma effect is desired. Single daily dosing is acceptable for users prioritizing simplicity and accepting transient peak-trough variation.

  • Single dose vs. split doses: Split dosing (twice daily) is preferred for systemic effects given the short half-life. Single evening dosing is acceptable when sedation is desirable or topical use is the primary modality.

  • Genetic considerations: Individuals with reduced UGT1A1 activity (e.g., Gilbert’s syndrome variants) may achieve effective plasma concentrations at lower doses; conversely, high-activity variants may require upper-end dosing. Pharmacogenetic testing for dihydromyricetin is not standard.

  • Sex-based considerations: Sex-specific dose-response data are not available. Body-weight-adjusted dosing is reasonable but not validated; women at the lower end of the body-weight range may consider starting at 250 mg.

  • Age-related considerations: Older users (>65) should generally start at the lower end of the dose range (100–250 mg/day) given reduced hepatic clearance and increased GABAergic sensitivity. Topical formulations may be preferable for older users sensitive to systemic effects.

  • Baseline biomarker considerations: Users with elevated baseline oxidative or inflammatory markers may have more measurable response. Users with normal markers may not detect a measurable change but may still derive benefit on visible skin endpoints.

  • Pre-existing condition considerations: Users with mild liver enzyme elevations should begin at lower doses with follow-up testing. Users with significant photoaging or hyperpigmentation may prioritize topical use; users with systemic inflammatory load may emphasize oral use.

Discontinuation & Cycling

  • Lifelong vs. short-term: Dihydromyricetin is not established as a lifelong intervention for skin rejuvenation; most rationales support multi-month courses (3–6 months) followed by reassessment of visible and biomarker outcomes.

  • Withdrawal effects: No significant withdrawal syndrome has been described. Theoretical concern exists about a brief rebound in anxiety or sleep quality after discontinuation in users who have used it primarily for GABAergic effects, but this has not been well documented.

  • Tapering: Tapering is generally unnecessary for short-term use. For users on prolonged daily dosing above 500 mg/day, a 1–2 week tapering period is reasonable as a precaution.

  • Cycling for maintained efficacy: No evidence supports a specific cycling regimen for skin endpoints. Some practitioners recommend a “5 days on, 2 days off” pattern or 8-weeks-on/2-weeks-off cycling to mitigate theoretical receptor adaptation and to allow tolerance assessment, but this is not based on dihydromyricetin-specific human data.

  • Discontinuation triggers: Persistent gastrointestinal discomfort beyond two weeks, new abnormal liver enzymes, contact dermatitis from topical use, or excessive daytime sedation are all reasonable triggers for discontinuation or dose reduction.

Sourcing and Quality

  • Source plants: Most commercial dihydromyricetin is extracted from Ampelopsis grossedentata (vine tea) leaves, with some products sourced from Hovenia dulcis (Japanese raisin tree). Extract concentrations vary widely; products labeled “vine tea extract” without standardization may contain less than 10% dihydromyricetin, while “purified dihydromyricetin” or “98% ampelopsin” preparations contain a defined active.

  • Standardization: Look for products labeled with a specific dihydromyricetin or ampelopsin percentage (typically 98% or higher for purified products) and stated milligram content of the active per serving. Products that list only “extract” without a standardization percentage are difficult to dose reproducibly.

  • Third-party testing: Look for products with third-party testing for identity, purity, heavy metals, microbial contamination, and pesticides. NSF, USP, ConsumerLab (where available), or Eurofins certifications are useful indicators. Vine tea raw material can carry pesticide residues if not sourced from controlled cultivation.

  • Formulation considerations: Standard powder formulations have low oral bioavailability. Phytosome or phospholipid-complexed formulations, nanoencapsulated forms, and salt forms (sodium dihydromyricetin) are available with claims of improved absorption; controlled human pharmacokinetic comparisons among these formulations are limited.

  • Topical formulations: For topical use, look for formulations specifying dihydromyricetin concentration (0.1–1% is typical), pH (slightly acidic for stability), packaging (opaque, air-restrictive packaging extends shelf life), and inclusion of complementary actives (vitamin C derivatives, niacinamide, ferulic acid). Avoid clear-jar formulations for any polyphenol active.

  • Reputable suppliers: Established botanical-extract suppliers with documented good manufacturing practices and Certificate of Analysis availability are preferable; programs such as NSF Certified for Sport, USP Verified, and Eurofins-tested raw-material certificates are useful indicators of identity and contaminant control. Standardized dihydromyricetin capsules with stated active percentages are the most reproducible finished-product category. Compounding pharmacies accredited by the Pharmacy Compounding Accreditation Board (PCAB) can prepare custom-concentration dihydromyricetin formulations on prescription, which can be useful for non-standard dose targets.

  • Storage: Dihydromyricetin is sensitive to light, oxygen, and heat. Store finished products at room temperature in tightly closed, opaque containers; topical formulations should be kept in air-restrictive packaging.

Practical Considerations

  • Time to effect: Mechanistic effects (Nrf2 activation, plasma antioxidant changes) occur within hours to days of dosing. Visible skin changes from topical use, when they occur, generally require 8–12 weeks of consistent use to become detectable, consistent with skin’s epidermal turnover cycle and the longer timescale for dermal collagen change. Oral systemic effects on skin endpoints may take 12 weeks or longer.

  • Common pitfalls: Underdosing relative to the standardization percentage of the chosen product (using a 30%-extract product at the dose appropriate for a 98%-purified product); abandoning the protocol before 12 weeks; combining with multiple GABAergic agents and attributing sedation only to one; relying on poor-bioavailability formulations for systemic effects; expecting topical-grade visible results from oral-only dosing.

  • Regulatory status: Dihydromyricetin is sold as a dietary supplement in the United States and most jurisdictions. It is not approved by the U.S. Food and Drug Administration (FDA) for any therapeutic indication. Cosmetic use of dihydromyricetin in topical products is permitted in most jurisdictions but is regulated as a cosmetic ingredient rather than a drug. Off-label and cosmetic uses are subject to standard supplement and cosmetic safety oversight.

  • Cost and accessibility: Dihydromyricetin supplements are widely available and moderately priced, generally $0.30–$1.00 per 300 mg dose for purified products. Topical formulations are more variable in price, ranging from inexpensive vine-tea-based serums to premium cosmetic-active products. Vine tea itself is inexpensive and widely available in Asian groceries and online.

Interaction with Foundational Habits

  • Sleep: Direct interaction. Dihydromyricetin’s GABA-A positive allosteric modulation can support sleep onset and depth, particularly in evening dosing. The proposed mechanism is enhancement of inhibitory neurotransmission. Practical consideration: evening dosing aligns the GABAergic effect with sleep, but consistent late-evening dosing may produce next-morning grogginess in sensitive users; mid-evening dosing (3–4 hours before bed) generally avoids this. Topical evening application also aligns with overnight skin repair processes.

  • Nutrition: Indirect, potentiating. Dihydromyricetin absorption modestly improves when taken with a fat-containing meal due to the lipophilic character of the molecule. Polyphenol-rich diets (berries, dark chocolate, green tea, vegetables) provide complementary antioxidant activity through partly overlapping pathways. Avoid taking with very high-tannin beverages immediately, as tannins can complex with flavonoids and reduce absorption. Practical consideration: take with breakfast and dinner that include some fat; integrate with broader polyphenol-rich nutrition rather than as a standalone strategy.

  • Exercise: Indirect, potentially blunting in some scenarios. Acute high-dose antioxidants taken immediately before strength training have been reported to attenuate post-exercise reactive-oxygen-species signaling and the resulting hypertrophic adaptation, primarily described for vitamins C and E. The same theoretical concern applies to high-dose dihydromyricetin. Practical consideration: separate dihydromyricetin dosing from resistance training by at least 4–6 hours when training adaptation is a priority; aerobic and skin-focused outcomes are unlikely to be affected.

  • Stress management: Direct, potentiating. The GABA-A activity of dihydromyricetin overlaps mechanistically with stress-management interventions (slow breathing, meditation, progressive muscle relaxation) that increase parasympathetic tone. Practical consideration: dihydromyricetin can complement non-pharmacological stress-management strategies; chronic high-dose use as a substitute for stress-management practice is not advisable. Effects on cortisol have not been clearly demonstrated in human studies.

Monitoring Protocol & Defining Success

Baseline assessment is appropriate before starting an oral protocol, and ongoing monitoring is reasonable for users on long-term or higher-dose regimens.

Ongoing monitoring should be done at baseline, at 8–12 weeks, and then every 6 months for users continuing on long-term oral protocols. Topical-only users generally do not require laboratory monitoring.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
ALT <19 U/L (women), <30 U/L (men) Detect any hepatic strain at higher doses Alanine aminotransferase (a liver enzyme whose elevation indicates hepatocyte injury). Conventional reference upper limit is often 40–55 U/L; functional medicine targets are tighter. Fasting is not required.
AST <22 U/L (women), <26 U/L (men) Detect any hepatic strain at higher doses Aspartate aminotransferase (a liver enzyme whose elevation indicates hepatocyte injury). Conventional reference upper limit is often 40 U/L. Pair with ALT and GGT for a complete hepatic picture.
GGT <16 U/L (women), <20 U/L (men) Sensitive marker of hepatobiliary stress Gamma-glutamyl transferase (a liver/biliary enzyme that also reflects oxidative stress and alcohol exposure). Conventional reference upper limit is often 50 U/L.
Bilirubin (total) 0.5–1.2 mg/dL Detect altered hepatic conjugation Mildly elevated unconjugated bilirubin is common in Gilbert’s syndrome; not concerning in isolation but informs UGT1A1 status.
hs-CRP <1.0 mg/L Reflect systemic inflammation responsive to anti-inflammatory effects High-sensitivity C-reactive protein (a general marker of systemic inflammation). Conventional cardiovascular-risk thresholds use <1.0 mg/L (low), 1.0–3.0 mg/L (average), and >3.0 mg/L (high); functional medicine targets the lower end of this range. Fasting not required; avoid testing during acute illness.
Fasting glucose 70–90 mg/dL Background metabolic context Conventional reference range is 70–99 mg/dL; functional medicine targets the lower end of this range to identify early dysglycemia. 12-hour fast required.
Fasting insulin 2–6 μIU/mL Background metabolic context 12-hour fast required; pair with glucose for a HOMA-IR (Homeostasis Model Assessment of Insulin Resistance, a calculated index of insulin resistance) calculation.
25-hydroxy vitamin D 40–60 ng/mL Background skin and immune health Not specific to dihydromyricetin but supports overall skin health context.
Comprehensive metabolic panel Standard ranges Baseline organ function Includes electrolytes, kidney function (creatinine, blood urea nitrogen), and liver enzymes.
Skin biomarker assessment (optional) N/A Document baseline visible skin status Standardized photography under consistent lighting; instrumented measures (cutometer for elasticity, corneometer for hydration) are available in dermatology and research contexts.

Qualitative markers worth tracking:

  • Visible skin tone uniformity and any changes in hyperpigmentation
  • Skin texture and tactile smoothness
  • Subjective sense of skin hydration and resilience
  • Sleep onset latency and sleep quality (relevant given GABAergic activity)
  • Daytime alertness and cognitive clarity
  • Subjective stress and anxiety levels
  • Any new gastrointestinal symptoms
  • Any topical reactions, redness, or itching at application sites

Emerging Research

  • Improved-bioavailability formulations: Several research groups are evaluating phospholipid-complex (phytosome), nanoemulsion, and self-emulsifying drug delivery systems to overcome dihydromyricetin’s low oral bioavailability. Bioavailability-enhanced formulations may meaningfully change the clinical signal in skin endpoints by raising achievable tissue concentrations. Liu et al., 2019 (PMID 32288229) reviews the formulation landscape and approaches to enhancing bioavailability.

  • Targeted topical formulations for melasma and post-inflammatory hyperpigmentation: Cosmetic-science groups in East Asia are evaluating standardized topical dihydromyricetin formulations for hyperpigmentation, leveraging the tyrosinase-inhibition mechanism. Trial registration entries have appeared on Asian trial registries; corresponding entries on clinicaltrials.gov are limited. Studies completed in this area in the next 2–3 years could establish a clinical signal that current evidence does not support.

  • Anti-fibrotic and wound-healing applications: Animal studies suggest dihydromyricetin may modulate transforming growth factor beta (TGF-β) signaling relevant to scar formation and wound healing. Translation to controlled human studies in post-procedure wound healing or hypertrophic scarring would be informative. Sun et al., 2021 (PMID 35115939) discusses the mechanistic basis across NF-κB, Nrf2, and cytokine pathways.

  • Senolytic and senomorphic activity: A small number of preclinical studies suggest dihydromyricetin may have senomorphic activity (suppressing the senescence-associated secretory phenotype, the inflammatory output of aged cells) in dermal fibroblasts. This is a frontier area where further preclinical and translational work could meaningfully shift the relevance to skin aging. No clinical trials in this indication have been registered as of the search date.

  • Structural derivatives and prodrugs: Medicinal chemistry programs have synthesized dihydromyricetin derivatives with improved stability, solubility, and target selectivity. Some derivatives report substantially higher in vitro tyrosinase-inhibition potency. Whether these will progress to clinical evaluation is open; if successful, they may displace native dihydromyricetin in the topical-active market.

  • Negative-direction research: Independent replication of bioavailability-enhanced formulations, more rigorous patch-testing for topical hypersensitivity, and longer-duration safety studies at typical supplemental doses would all be informative. If bioavailability-enhanced products produce only marginal skin endpoints, the case for systemic use specifically for skin rejuvenation may weaken; conversely, if controlled topical trials show no measurable visible benefit at typical concentrations, the topical case may also weaken.

  • Ongoing clinical trials: As of the search date, clinicaltrials.gov registrations for dihydromyricetin and skin endpoints are limited. Existing dihydromyricetin trials are focused primarily on alcohol- and liver-related outcomes (e.g., NCT05623501, a first-in-human Phase 1 open-label dose-escalation study at the University of Southern California, n=12 healthy volunteers in 4 cohorts (300 mg or 900 mg dihydromyricetin, with or without L-lysine), with primary endpoints of pharmacokinetics of dihydromyricetin metabolites and adverse events graded by CTCAE (Common Terminology Criteria for Adverse Events, a standardized scale for grading the severity of adverse events) v3.0, as a foundation for evaluation in alcohol-associated liver disease) rather than dermatologic endpoints. The most current trial landscape can be reviewed via clinicaltrials.gov searches for “dihydromyricetin” and “ampelopsin”.

Conclusion

Dihydromyricetin is a flavonoid with a long traditional use, a coherent mechanistic story relevant to skin biology, and a small but suggestive preclinical record on oxidative stress, hyperpigmentation, collagen preservation, and inflammatory skin conditions. It is well-tolerated at typical supplemental doses, with the most consistent caveat being dose-dependent sedation from its action on the brain’s main inhibitory signaling system, modest gastrointestinal effects, and a small risk of topical hypersensitivity.

The evidence specifically supporting dihydromyricetin for skin rejuvenation remains preliminary. Most positive findings come from cell-based and animal studies; controlled human trials with visible skin endpoints are scarce. Oral bioavailability is low, which raises legitimate questions about how much dihydromyricetin reaches skin tissue from supplemental dosing. Topical formulations bypass this concern but introduce their own variability in concentration and stability across products. The mechanistic plausibility is strong; the human clinical record on visible skin endpoints is sparse.

For a longevity-oriented audience already maintaining the foundational habits, dihydromyricetin sits in a category of mechanistically plausible, low-cost, well-tolerated additions where the upside on skin endpoints is uncertain but the downside is modest. The strength of the case is greatest for topical application targeting hyperpigmentation, less established for systemic skin-aging effects, and largely speculative for visible wrinkle improvement. The current evidence base on visible skin endpoints remains preliminary, with the topical-active research direction the most active and the systemic-supplement direction the most uncertain.

Top - Benefits - Risks - Protocol